CA2432736A1 - Silenced anti-cd28 antibodies and use thereof - Google Patents

Silenced anti-cd28 antibodies and use thereof Download PDF

Info

Publication number
CA2432736A1
CA2432736A1 CA002432736A CA2432736A CA2432736A1 CA 2432736 A1 CA2432736 A1 CA 2432736A1 CA 002432736 A CA002432736 A CA 002432736A CA 2432736 A CA2432736 A CA 2432736A CA 2432736 A1 CA2432736 A1 CA 2432736A1
Authority
CA
Canada
Prior art keywords
antibody
cells
seq
antibodies
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002432736A
Other languages
English (en)
French (fr)
Inventor
J. Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2432736A1 publication Critical patent/CA2432736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002432736A 2000-12-14 2001-12-14 Silenced anti-cd28 antibodies and use thereof Abandoned CA2432736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US60/255,155 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (1)

Publication Number Publication Date
CA2432736A1 true CA2432736A1 (en) 2002-06-20

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002432736A Abandoned CA2432736A1 (en) 2000-12-14 2001-12-14 Silenced anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (cs)
JP (1) JP2004515243A (cs)
KR (1) KR20040020866A (cs)
CN (1) CN1272345C (cs)
AR (1) AR031924A1 (cs)
AU (2) AU2608602A (cs)
BR (1) BR0116686A (cs)
CA (1) CA2432736A1 (cs)
CZ (1) CZ20031909A3 (cs)
HU (1) HUP0400697A3 (cs)
IL (1) IL156262A0 (cs)
MX (1) MXPA03005327A (cs)
NO (1) NO20032542L (cs)
NZ (1) NZ526569A (cs)
PL (1) PL363239A1 (cs)
RU (1) RU2261723C2 (cs)
WO (1) WO2002047721A1 (cs)
ZA (1) ZA200305384B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EA012801B1 (ru) 2005-06-14 2009-12-30 Эмджен Инк. Самобуферирующиеся композиции белков
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
ES2680570T3 (es) * 2010-02-18 2018-09-10 Ose Immunotherapeutics Anticuerpos humanizados anti-CD28
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20220153845A1 (en) * 2019-03-14 2022-05-19 Biond Biologics Ltd. A method for immunosuppression
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
AU2021329378A1 (en) 2020-08-19 2023-03-23 Xencor, Inc. Anti-CD28 compositions
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
HUP0400697A3 (en) 2007-05-02
IL156262A0 (en) 2004-01-04
EP1341553A4 (en) 2004-07-28
NZ526569A (en) 2005-07-29
CN1489473A (zh) 2004-04-14
NO20032542D0 (no) 2003-06-05
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
RU2261723C2 (ru) 2005-10-10
ZA200305384B (en) 2004-10-11
AU2002226086C1 (en) 2006-03-09
AR031924A1 (es) 2003-10-08
RU2003121231A (ru) 2005-02-10
HUP0400697A2 (hu) 2004-06-28
BR0116686A (pt) 2003-12-30
WO2002047721A1 (en) 2002-06-20
PL363239A1 (en) 2004-11-15
JP2004515243A (ja) 2004-05-27
MXPA03005327A (es) 2004-12-03
CN1272345C (zh) 2006-08-30
CZ20031909A3 (cs) 2003-11-12
AU2608602A (en) 2002-06-24
AU2002226086B2 (en) 2005-08-25
EP1341553A1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
EP0966485B1 (en) MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME
RU2244720C2 (ru) Антитело igg с аффинностью связывания в отношении антигенного комплекса cd3, рекомбинантные нуклеиновые кислоты, кодирующие легкую и тяжелую цепи антитела, способ получения системы, способ получения антитела, способ лечения пациента
US6129914A (en) Bispecific antibody effective to treat B-cell lymphoma and cell line
JP4066166B2 (ja) 抗−ｃｄ２８抗体
KR100191152B1 (ko) Cd4 특이적 재조합 항체
US20040052783A1 (en) Humanized antibodies against CD3
AU2002226086B2 (en) Silensed anti-CD28 antibodies and use thereof
US20050202022A1 (en) Polynucleotides encoding humanized antibodies against human 4-1BB
KR20050111748A (ko) 면역억제 특성을 가진 인간화 항-ｃｄ4 항체
WO1996032495A1 (en) Monoclonal antibody specific for human 4-1bb and cell line producing same
AU2671699A (en) Antibodies against human cd40
KR20070036138A (ko) 영장류에서 관용 유발을 위한 항-ｃｄ４ 항체를 사용하는최적화 용량 결정
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
MXPA01008098A (es) Inmunoglobulina humanizada reactiva con moleculas b7 y metodo de tratamiento con el mismo.
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof
GB2376467A (en) TRX1 Antibodies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued